⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532554 | 1.00 | — | — | |
| SCHEMBL221974 | 1.00 | — | — | |
| SCHEMBL5183891 | 1.00 | — | — | |
| SCHEMBL3623222 | 1.00 | — | — | |
| SCHEMBL329683 | 1.00 | — | — | |
| SCHEMBL37974 | 1.00 | — | — | |
| SCHEMBL532553 | 1.00 | — | — | |
| SCHEMBL348997 | 1.00 | — | — | |
| SCHEMBL1607814 | 1.00 | — | — | |
| SCHEMBL2152717 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RIBOZYME PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-6586238-B1 | Modified ribozymes; useful for cleavage of RNA or single-stranded DNA; Resistance to exonuclease degradation | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-4387657-A1 | LIPID NANOPARTICLE FORMULATIONS | Monash University (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| CN-118108813-A | S protein mutant of 2019-nCoV Omicron strain and genetically engineered mRNA thereof | 北京启辰生生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118103509-A | MiRNA combinations for the prevention and treatment of cancer | 利昂贝拉尔中心 | 2024-05-28 | — | — | CN | disclosed |
| CN-118064466-A | Polynucleotide for coding recombinant interleukin 12 and application thereof | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118019752-A | Compositions comprising hydroxyethyl-terminated cationic peptides | 胡桃钳医疗公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| CN-101263230-A | Pharmaceutical compositions for delivering ribonucleic acid to cells | NASTECH PHARM CO (US) | 2008-09-10 | — | — | CN | disclosed |
| US-20080171716-A1 | A nucleic acid having a 2-methylated nucleotide and a gene expression inhibiting nucleic acid that does not induce cytokine production ; a nucleic acid-lipid conjugate optionally containing polyethylene glycol; antiarthritic agents; systemic lupus erythematosus, multiple sclerosis | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2007137301-A2 | MODULATION OF CHREBP EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070218122-A1 | siRNA silencing of influenza virus gene expression | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070135370-A1 | siRNA molecule for silencing Ebola virus L-polymerase (L-pol) expression; nucleic acid-lipid particles suitable for use in intravenous nucleic acid delivery as they are stable in circulation, of a size required for pharmacodynamic behavior resulting in access to extravascular sites, and target cell | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2007-06-14 | — | — | US | disclosed |
| US-20070135372-A1 | Modified siRNA molecules and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2007-06-14 | — | — | US | disclosed |
| US-20060134189-A1 | siRNA silencing of apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |